Health Care • Other Pharmaceuticals
$994.58 ▲ +13.70
(+1.40%)
MKT CAP: $114.36B • VOL: 763.2K
52W L $724 52W H $1,030
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$835
MEDIAN
$1,114
MEAN
$1,134
HIGH
$1,353
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MCK TAPE
MCK // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $1,203.44 | $1,143.77 | 2025-02-14 | $905.07 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $1,253.17 | $1,173.60 | 2025-02-06 | $934.91 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $1,133.82 | $1,094.04 | 2025-01-29 | $954.80 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $1,014.47 | — | 2025-01-17 | $974.69 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $875.23 | $944.85 | 2025-01-09 | $885.18 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $1,183.55 | $1,034.36 | 2024-12-18 | $865.28 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $964.74 | $1,004.53 | 2024-12-04 | $924.96 | -4.3% | 48% | C |